News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hadasit Ltd., Hadassah Medical Organization and Brigham and Women's Hospital Announce the Successful Phase I Study Results of a New Orally Administered Drug for Autoimmune Diseases



4/16/2008 8:40:22 AM

JERUSALEM & BOSTON--(BUSINESS WIRE)--Hadasit, the technology transfer company of Hadassah Medical Organization in Jerusalem, and Brigham and Women’s Hospital (BWH), a teaching affiliate of Harvard Medical School, announced today the successful results of a Phase I study of a new orally administered drug for immune mediated diseases such as diabetes, Crohn's disease, psoriasis, multiple sclerosis, and liver diseases. The trial was announced in January 2008.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES